Theraclone raises $14M to ID rare human antibodies that could be used to fight disease

theraclone22

Seattle biotechnology company Theraclone Sciences has raised an additional $8 million in equity financing and $6 million in debt, bringing total investment in its series B funding to $50 million. Investors in the round included ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo. “Theraclone… Read More…

Tech Moves: Mobilisafe adds marketing VP; Theraclone names CEO; BigDoor; etc.

Sahay

Sajal Sahay has joined Seattle mobile security upstart Mobilisafe as vice president of marketing with the goal of helping to bring the company’s first products to market. “Device security is one of the key megatrends in the mobile industry, and Mobilisafe is poised to transform the category with a simple yet effective solution that is… Read More…

Theraclone Sciences raises $10M

theraclone11

Theraclone Sciences, a Seattle biotechnology company that’s developing a method to rapidly identify disease-fighting antivbodies, has attracted $10.6 million. Investors in the deal include ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo “The anticipated near-term initiation of Theraclone’s first clinical trial and our discovery collaboration with Pfizer earlier… Read More…